Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

NCT02039219 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Post-marketing reports of hepatotoxicity associated with obeticholic acid emerged in June 2017, investigators temporarily halted patient recruitment June 2017.

Conditions

Alcoholic Hepatitis

Interventions

DRUG: Placebo
DRUG: 10 mg Obeticholic Acid (OCA)

Sponsor

Naga P. Chalasani

Collaborators

[object Object]
[object Object]